Heart failure is a debilitating condition that develops when the heart cannot supply adequate circulation . Credit: Bryan Brandenburg.

Boehringer Ingelheim and Eli Lilly have reported positive top-line data from the Phase III EMPEROR-Reduced clinical trial of Jardiance (empagliflozin) in adults with reduced ejection fraction heart failure, with and without diabetes.

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.

By downloading this case study, you acknowledge that GlobalData may share your information with Oximio and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial met its primary endpoint, where the drug showed superiority over placebo in mitigating the risk for the composite of cardiovascular death or hospitalisation related to heart failure, when given with standard of care.

Overall the safety profile was observed to be similar to the drug’s known profile.

Boehringer Ingelheim Pharmaceuticals Cardio-Metabolism & Respiratory Medicine clinical development & medical affairs vice-president Mohamed Eid said: “With these positive top-line results from the EMPEROR-Reduced trial, we are excited to mark another important advancement for Jardiance.

“There is an urgent need for new heart failure treatments, and these results show promise for the potential role Jardiance can play in improving the lives of adults living with this condition.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Jardiance is a prescription drug indicated for use with a healthy diet and exercise to lower blood sugar in adults with type 2 diabetes.

The drug is also used to decrease the risk of cardiovascular death in type 2 diabetes patients with known cardiovascular disease.

EMPEROR-Reduced assessed the safety and efficacy of Jardiance in patients with heart failure with reduced ejection fraction in a total of 3,730 patients.

The study is part of the EMPEROR Heart Failure Studies, including EMPEROR-Preserved, which is investigating the safety and efficacy of Jardiance in around 5,990 patients with preserved ejection fraction heart failure.

Results from EMPEROR-Preserved are expected to be reported next year.

The EMPEROR trials fall under the EMPOWER clinical programme, which is assessing the impact of the drug on the lives of people with a variety of cardio-renal-metabolic conditions.

In May this year, Boehringer and Lilly partnered with the Duke Clinical Research Institute (DCRI) to conduct the EMPACT-MI trial of Jardiance to prevent heart failure.